55.67
Belite Bio Inc Adr stock is traded at $55.67, with a volume of 52,456.
It is down -1.67% in the last 24 hours and down -11.46% over the past month.
See More
Previous Close:
$56.90
Open:
$53.18
24h Volume:
52,456
Relative Volume:
1.27
Market Cap:
$1.65B
Revenue:
-
Net Income/Loss:
$-32.61M
P/E Ratio:
-47.41
EPS:
-1.1742
Net Cash Flow:
-
1W Performance:
-15.51%
1M Performance:
-11.46%
6M Performance:
+9.92%
1Y Performance:
+41.22%
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BLTE
Belite Bio Inc Adr
|
55.67 | 1.65B | 0 | -32.61M | 0 | -1.1742 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
550.00 | 32.85B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 28.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-14-23 | Initiated | Maxim Group | Buy |
Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
Jul-26-23 | Initiated | SVB Securities | Outperform |
Aug-01-22 | Initiated | H.C. Wainwright | Buy |
Jul-01-22 | Initiated | The Benchmark Company | Buy |
Belite Bio Inc Adr Stock (BLTE) Latest News
Belite Bio, Inc. Appoints New Auditor - TipRanks
Benchmark Reiterates Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World
Belite Bio stock target raised to $80 at Benchmark By Investing.com - Investing.com South Africa
Belite Bio price target raised to $80 from $79 at Benchmark - TipRanks
Belite Bio stock target raised to $80 at Benchmark - Investing.com
Belite Bio, Inc. ADR: Promising Clinical Progress and Strong Financial Position Drive Buy Rating - TipRanks
Cantor Fitzgerald Forecasts Weaker Earnings for Belite Bio - Defense World
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Up 17.1% in February - Defense World
HC Wainwright Has Pessimistic View of Belite Bio Q1 Earnings - Defense World
Belite Bio (NASDAQ:BLTE) Receives Buy Rating from HC Wainwright - Defense World
Belite Bio’s (BLTE) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Belite Bio’s Earnings Call: Cautious Optimism Amid Progress - TipRanks
Belite Bio Announces 2025 Annual Shareholder Meeting - TipRanks
Belite Bio stock holds $100 target post-results - Investing.com India
Positive Buy Rating for Belite Bio, Inc. Driven by Promising Phase 3 DRAGON Trial Results and Regulatory Prospects - TipRanks
Belite Bio (NASDAQ:BLTE) Shares Gap Down After Earnings Miss - Defense World
Belite Bio Advances in Retinal Disease Trials and Financial Position - TipRanks
Earnings call transcript: Belite Bio ADR Q4 2024 sees steady R&D progress - Investing.com Australia
Belite Bio reports Q4 EPS (32c), consensus (31c) - TipRanks
Belite Bio Reports 2024 Financial Results and Clinical Progress - TipRanks
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website - Markets Insider
Belite Bio Releases 2024 Annual Report on Website - TipRanks
Belite Bio Reports Positive Interim Analysis Results for Phase 3 DRAGON Trial and Financial Update for Q4 2024 - Nasdaq
Public market insider buying at Savaria (SIS) - The Globe and Mail
Belite Bio's $145M War Chest Powers Critical Phase 3 Eye Disease Trial - StockTitan
Belite Bio (NASDAQ:BLTE) Trading Down 1.6% – Time to Sell? - Defense World
Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics - The Globe and Mail
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 ... - The Bakersfield Californian
Biotech Pioneer Belite Bio Unveils Q4 and 2024 Performance: Key Retinal Disease Updates Coming March 17 - Stock Titan
Is Meta Platforms Stock a Buy, Sell, or Hold Ahead of Llama 4 Launch? - The Globe and Mail
Parkland Reports Fourth Quarter and Year-End 2024 Results; Initiates Review of Strategic Alternatives - The Globe and Mail
Darwin CX Expands Internationally, Aiming to Tackle Global Publishing Challenges with Locally Tailored Solutions - The Globe and Mail
Can Belite Bio's Retinal Disease Treatments Impress Investors at Upcoming Leerink Conference? - StockTitan
2 Large-Cap Stocks with Exciting Potential and 1 to Avoid - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Shares Gap UpShould You Buy? - MarketBeat
Promising Phase 3 Results for Belite Bio’s Tinlarebant in Stargardt Disease Boost Buy Rating - TipRanks
Belite Bio’s Phase 3 Trial for Stargardt Disease Drug Advances - TipRanks
Belite Bio Announces Interim Analysis Results from the - GlobeNewswire
Can Belite Bio's Tinlarebant Become First Treatment for Stargardt Disease? Phase 3 Data Shows Promise - StockTitan
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume – Still a Buy? - The AM Reporter
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 9.2% in January - MarketBeat
Belite Bio (NASDAQ:BLTE) Stock Price Up 7.8%Should You Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Shares Down 4.7%Time to Sell? - MarketBeat
Advisors Preferred LLC Purchases New Shares in Belite Bio, Inc (NASDAQ:BLTE) - Armenian Reporter
Belite Bio Announces $15 Million Direct Offering to Enhance Financial Position - TipRanks
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):